Cargando…

The Complex Structure of the Pharmacological Drug–Disease Network

The complexity of drug–disease interactions is a process that has been explained in terms of the need for new drugs and the increasing cost of drug development, among other factors. Over the last years, diverse approaches have been explored to understand drug–disease relationships. Here, we construc...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Rodríguez, Irene, Reyes-Manzano, Cesár F., Guzmán-Vargas, Ariel, Guzmán-Vargas, Lev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466955/
https://www.ncbi.nlm.nih.gov/pubmed/34573762
http://dx.doi.org/10.3390/e23091139
_version_ 1784573273125683200
author López-Rodríguez, Irene
Reyes-Manzano, Cesár F.
Guzmán-Vargas, Ariel
Guzmán-Vargas, Lev
author_facet López-Rodríguez, Irene
Reyes-Manzano, Cesár F.
Guzmán-Vargas, Ariel
Guzmán-Vargas, Lev
author_sort López-Rodríguez, Irene
collection PubMed
description The complexity of drug–disease interactions is a process that has been explained in terms of the need for new drugs and the increasing cost of drug development, among other factors. Over the last years, diverse approaches have been explored to understand drug–disease relationships. Here, we construct a bipartite graph in terms of active ingredients and diseases based on thoroughly classified data from a recognized pharmacological website. We find that the connectivities between drugs (outgoing links) and diseases (incoming links) follow approximately a stretched-exponential function with different fitting parameters; for drugs, it is between exponential and power law functions, while for diseases, the behavior is purely exponential. The network projections, onto either drugs or diseases, reveal that the co-ocurrence of drugs (diseases) in common target diseases (drugs) lead to the appearance of connected components, which varies as the threshold number of common target diseases (drugs) is increased. The corresponding projections built from randomized versions of the original bipartite networks are considered to evaluate the differences. The heterogeneity of association at group level between active ingredients and diseases is evaluated in terms of the Shannon entropy and algorithmic complexity, revealing that higher levels of diversity are present for diseases compared to drugs. Finally, the robustness of the original bipartite network is evaluated in terms of most-connected nodes removal (direct attack) and random removal (random failures).
format Online
Article
Text
id pubmed-8466955
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84669552021-09-27 The Complex Structure of the Pharmacological Drug–Disease Network López-Rodríguez, Irene Reyes-Manzano, Cesár F. Guzmán-Vargas, Ariel Guzmán-Vargas, Lev Entropy (Basel) Article The complexity of drug–disease interactions is a process that has been explained in terms of the need for new drugs and the increasing cost of drug development, among other factors. Over the last years, diverse approaches have been explored to understand drug–disease relationships. Here, we construct a bipartite graph in terms of active ingredients and diseases based on thoroughly classified data from a recognized pharmacological website. We find that the connectivities between drugs (outgoing links) and diseases (incoming links) follow approximately a stretched-exponential function with different fitting parameters; for drugs, it is between exponential and power law functions, while for diseases, the behavior is purely exponential. The network projections, onto either drugs or diseases, reveal that the co-ocurrence of drugs (diseases) in common target diseases (drugs) lead to the appearance of connected components, which varies as the threshold number of common target diseases (drugs) is increased. The corresponding projections built from randomized versions of the original bipartite networks are considered to evaluate the differences. The heterogeneity of association at group level between active ingredients and diseases is evaluated in terms of the Shannon entropy and algorithmic complexity, revealing that higher levels of diversity are present for diseases compared to drugs. Finally, the robustness of the original bipartite network is evaluated in terms of most-connected nodes removal (direct attack) and random removal (random failures). MDPI 2021-08-31 /pmc/articles/PMC8466955/ /pubmed/34573762 http://dx.doi.org/10.3390/e23091139 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
López-Rodríguez, Irene
Reyes-Manzano, Cesár F.
Guzmán-Vargas, Ariel
Guzmán-Vargas, Lev
The Complex Structure of the Pharmacological Drug–Disease Network
title The Complex Structure of the Pharmacological Drug–Disease Network
title_full The Complex Structure of the Pharmacological Drug–Disease Network
title_fullStr The Complex Structure of the Pharmacological Drug–Disease Network
title_full_unstemmed The Complex Structure of the Pharmacological Drug–Disease Network
title_short The Complex Structure of the Pharmacological Drug–Disease Network
title_sort complex structure of the pharmacological drug–disease network
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466955/
https://www.ncbi.nlm.nih.gov/pubmed/34573762
http://dx.doi.org/10.3390/e23091139
work_keys_str_mv AT lopezrodriguezirene thecomplexstructureofthepharmacologicaldrugdiseasenetwork
AT reyesmanzanocesarf thecomplexstructureofthepharmacologicaldrugdiseasenetwork
AT guzmanvargasariel thecomplexstructureofthepharmacologicaldrugdiseasenetwork
AT guzmanvargaslev thecomplexstructureofthepharmacologicaldrugdiseasenetwork
AT lopezrodriguezirene complexstructureofthepharmacologicaldrugdiseasenetwork
AT reyesmanzanocesarf complexstructureofthepharmacologicaldrugdiseasenetwork
AT guzmanvargasariel complexstructureofthepharmacologicaldrugdiseasenetwork
AT guzmanvargaslev complexstructureofthepharmacologicaldrugdiseasenetwork